Results of a prospective phase 2 pilot trial of Lu177 PSMA 617 therapy for metastatic castrate resistant prostate cancer including Imaging predictors of treatment response and patterns of progression.
Published 2018 View Full Article
Published 2018 View Full Article
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now